ArticleJournal of gastroenterology2021
Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.
Article in Journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Liver fibrosis stage based on the four factors (FIB-4) score or Forns index in adults with chronic hepatitis C.The Cochrane database of systematic reviews · 2024Pooled it
- A randomized clinical study to evaluate the possible antifibrotic effect of zinc sulfate in chronic HCV patient receiving direct-acting anti-viral therapy.Inflammopharmacology · 2025Trial
- Multicentre validation and comparison of 23 noninvasive diagnostic models for liver fibrosis in treatment-naïve Chinese patients with autoimmune hepatitis.BMC gastroenterology · 2026Article
- A novel non-invasive nomogram for predicting advanced liver fibrosis in autoimmune hepatitis.Scientific reports · 2026Article
- LIMITED DIAGNOSTIC ACCURACY OF FIB-4 FOR DETECTING SIGNIFICANT LIVER FIBROSIS IN CHRONIC HEPATITIS B: A CROSS-SECTIONAL STUDY.Arquivos de gastroenterologia · 2026Article
- Sequential Fibrosis-4 Index and Mac-2 Binding Protein Glycosylation Isomer Combination Improve Detection of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Study.Gastro hep advances · 2026Article
- Identifying liver cirrhosis in patients with chronic hepatitis B: an interpretable machine learning algorithm based on LSM.Annals of medicine · 2025Article
- Development and validation of a nomogram model for predicting acute hepatic dysfunction post-intervention in primary hepatocellular carcinoma: a retrospective case-control study.World journal of surgical oncology · 2025Article
- A diagnostic model based on transcriptomic analysis reveals inflammation as a potential prognosis factor for hepatoblastoma with hepatocellular carcinoma features.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease.Scientific reports · 2025Article
- Article
- Assessing the consistency of FIB-4, APRI, and GPR in evaluating significant liver fibrosis and cirrhosis in COVID-19 patients with concurrent liver diseases.BMC gastroenterology · 2025Article
- Aspartate Aminotransferase to Platelet Ratio Index (APRI), Göteborg University Cirrhosis Index (GUCI), and Fibrosis 4 Score (FIB-4) proved to be the optimal biomarkers for the assessment of liver fibrosis in patients chronically infected with hepatitis C virus in Brazil.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Hypermethylation of Ring finger protein 41 promoter is associated with early hepatitis B virus-related cirrhosis.Frontiers in medicine · 2025Article
- Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.Global health & medicine · 2024Article
- Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.Journal of gastroenterology · 2024Article
- Dose-response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B.Hepatology international · 2024Article
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation.Journal of gastroenterology · 2024Article
- A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.Cancer immunology, immunotherapy : CII · 2024Article
- Serum biomarkers for liver fibrosis assessment.Advances in laboratory medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe usefulness of APRI or FIB-4 is well established as a non-invasive liver fibrosis marker at a point of diagnosis in patients with chronic liver disease. However, their applicability for the monitoring of progression of liver fibrosis over time is yet to be determined. We aimed to clarify the feasibility of APRI and FIB-4 for the longitudinal evaluation of liver fibrosis in patients with chronic hepatitis B and C.
methodsThis is a multi-center retrospective and prospective cohort study, enrolling 1029 patients with HCV and 384 patients with HBV who were histologically diagnosed by liver biopsy. The observation period of retrospective and prospective study was 14 and 12 years, respectively. The APRI and FIB-4 were traced back in cases of histologically diagnosed cirrhosis, and those were prospectively analyzed after biopsy in cases diagnosed as F3 of METAVIR score, respectively.
resultsThe averaged APRI and FIB-4 exhibited time-dependent increase in the retrospective study of hepatitis C patients (increase by 0.09/year in APRI and 0.29/year in FIB-4). In the prospective study of untreated hepatitis C patients, such increases were 0.14/year in APRI and 0.40/year in FIB-4, respectively. Neither the average of APRI nor FIB-4 showed a specific tendency with hepatitis B patients and treatment-experienced hepatitis C patients.
conclusionThe APRI and FIB-4 may serve as a transition indicator of liver fibrosis in anti-viral treatment-naïve patients with chronic hepatitis C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.